B Cell Non-Hodgkin Lymphoma

CTSS is significantly elevated in patients with NHL and has the potential to be a new diagnostic bio - marker for the detection of NHL. Also, this study was the first to unveil the association between serum CTSS levels and the proportions of anti-apoptotic HDL3a and HDL3b subclasses in NHL patients.

In summary, RTX-IgG2 acts as a potent phagocytic enhancer by promoting Fc-receptor mediated phagocytosis through apoptosis and reduction of CD47 in CD20+ malignant B-cells. RTX-IgG2 represents a valuable therapeutic component in enhancing the effectiveness of different mAbs targeting B-cell NHL.

At day+1, higher plasma levels of lipid metabolism products and lower glucose and glycoproteins levels were observed in tisa-cel compared to axi-cel-treated patients. Our data show complex metabolomic changes that track the evolution of the disease and drug activity in the first 30 days of CAR-T cell therapy. Conceivably, a pro-inflammatory drift may be linked to a forthcoming disease relapse in CAR-T patients.

P2, N=30, Completed, AstraZeneca | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Oct 2024

In the group of five patients with indolent lymphoma and CD20 expression loss, three patients (60%) had concurrent transformation to high-grade lymphoma. This study, which reinforces the importance of repeating a biopsy at relapse before implementing CD20-directed therapy, is particularly relevant given the widespread use of rituximab along with the emerging significance of CD20-targeted bispecific antibodies in the management of B-cell lymphomas.

Amulirafusp alfa showed favorable safety profile and preliminary efficacy in patients with r/r B-NHL, meriting further investigation. Trial registration NCT05805943.

Immunohistochemical staining demonstrated positivity for cluster of differentiation 20 (CD20), CD10, and B-cell lymphoma 2 (BCL2), confirming the diagnosis of FL. Thus, we report this rare manifestation of FL presenting as an isolated omental mass.

P2, N=20, Recruiting, Northside Hospital, Inc. | Not yet recruiting --> Recruiting

P1/2, N=65, Recruiting, Hoffmann-La Roche | Trial primary completion date: Oct 2027 --> Mar 2027

P2, N=178, Recruiting, Ryvu Therapeutics SA | Not yet recruiting --> Recruiting

P1, N=121, Recruiting, Hoffmann-La Roche | Trial completion date: Jul 2028 --> Mar 2029 | Trial primary completion date: Jul 2026 --> Mar 2027

P1/2, N=543, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting

P=N/A, N=82, Completed, Eric Turcotte | Unknown status --> Completed

P1, N=114, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

P1, N=106, Recruiting, Umoja Biopharma | Not yet recruiting --> Recruiting

P2, N=34, Not yet recruiting, Northwestern University

P=N/A, N=60, Not yet recruiting, National Research Center for Hematology, Russia

P1, N=40, Recruiting, Atara Biotherapeutics | Initiation date: Jan 2024 --> Sep 2024

P1, N=226, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Dec 2024 --> Apr 2025

P1, N=45, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2026 --> Apr 2025 | Trial primary completion date: Nov 2024 --> Apr 2025

P1, N=75, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2026 --> Jul 2025

Further, despite adding a second antigen, antigen-negative relapses have not yet been eliminated. This review will summarise the state-of-the-art with dual targeting CAR-T cells for B-cell ALL and B-NHL, challenges encountered, and possible next steps to overcome them.

P1, N=36, Recruiting, Zhejiang University

P1, N=28, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025

P1/2, N=860, Recruiting, Hoffmann-La Roche | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026

P1/2, N=60, Recruiting, National Research Center for Hematology, Russia | Not yet recruiting --> Recruiting

At present, studies at home and abroad have confirmed that the 90-minute short duration infusion of obinutuzumab is safe and feasible.In order to improve the convenience of patient infusion and the efficiency of medical institutions'infusion facilities, it is recommended for patients who do not experience grade ≥3 infusion-related adverse reactions in the first cycle of obinutuzumab infusion at the standard rate, a short duration infusion scheme should be used for subsequent treatment courses. This expert consensus is formulated to provide guidance for clinical practice.

The patient received eight cycles of the CHOP (doxorubicin, cyclophosphamide, prednisone, and vincristine) chemotherapy regimen, achieving complete clinical remission with no recurrence noted at the two-year follow-up. Early recognition is crucial for optimal treatment of this uncommon disease. Further research is needed to refine treatment protocols.

Findings from this review will contribute to cancer nurses' knowledge of CD20-CD3 BsAbs for B-NHL, optimizing the quality and safety of patient care.

P2, N=240, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

P1, N=231, Recruiting, AstraZeneca | N=116 --> 231

P1, N=24, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

Finally, according to our model and computational drug sensitivity analysis, four small molecule compounds, BMS-754807, SB216763, Doramapimod, and Trametinib, were identified as potential therapeutic agents for patients with MCL. This study provides a prognostic model with ferroptosis-related gene signature for MCL. The results show that the model helps predict prognosis in MCL.

P1, N=100, Recruiting, Byondis B.V. | Trial primary completion date: Oct 2024 --> Oct 2025

P2, N=54, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025

P1/2, N=60, Not yet recruiting, National Research Center for Hematology, Russia

The TRIANGLE trial (Dreyling et al, Lancet 2024) suggested that auto-HCT may not add benefit to more effective induction and maintenance regimens containing high-dose cytarabine, rituximab and BTK inhibitors. Pts who remain MRD+ after induction may benefit from auto-HCT. Longer follow-up will be important to confirm these findings.

In vivo experiments further confirmed that targeting NAALADL2-AS2 effectively suppressed tumor growth, leading to upregulation of miR-34a and miR-125a, downregulation of BCL-2, and enhanced apoptosis in DLBCL cells, which significantly improved their sensitivity to doxorubicin and rituximab by approximately 50%. These results indicate that NAALADL2-AS2/miR-34a, miR-125a/BCL-2 networks hold promise as therapeutic targets for treatment of DLBCL.

EBV+ and EBV- PCNSL harbor distinct transcriptional and epigenetic profiles, corroborating them as distinctive biological subtypes. Uncovered differences provide novel insights into their pathobiology, may guide molecular diagnostics and targeted therapies.

Mice in the ISO group received an intraperitoneal injection of ISO (5 mg/kg) once daily for 9 days, and the administration group were injected with ISO after 5 days of treatment with geraniin or spironolactone...Furthermore, it suppressed the ISO-induced cellular apoptosis of hypertrophic cardiac tissue, as evidenced by the decrease in Bcell lymphoma-2 (Bcl-2)-associated X/caspase-3/caspase-9 expression, increase in Bcl-2 expression, and decrease in TdT-mediated dUTP nick-end labeling-positive cells. These findings suggest that geraniin can attenuate ISO-induced cardiac hypertrophy by inhibiting inflammation, oxidative stress and cellular apoptosis.

The patient's general condition recovered rapidly after laparoscopic surgery, and her clinical course proceeded smoothly to the initiation of chemotherapy(R-CHOP)at the Department of Hematology. The tumor remains in remission now. Here, we report a case of laparoscopic surgery for malignant lymphoma of the small intestine that caused bowel obstruction due to luminal narrowing along with a relevant literature review.

This is the first study to assess changes in lymphocytes, T cells, and CAR transgene levels in patients treated with BsAb after CAR-T. These findings suggest an interaction between prior CAR-T and BsAb outcomes, and have implications for optimal timing of BsAb after CAR-T.